(Q47567321)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

title

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Thomas A Hope

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Emily K Bergsland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Murat Fani Bozkurt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Anthony P Heaney

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Ken Herrmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Matthew H Kulke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Pamela L Kunz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Josh Mailman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Lawrence May

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

David C Metz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Corina Millo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Sue O'Dorisio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Diane L Reidy-Lagunes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Michael C Soulen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Jonathan R Strosberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

language of work or name

English

0 references

publication date

12 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Nuclear Medicine

7 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

page(s)

66-74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites

7 April 2020

cites work

1 reference

12 December 2020

Somatostatin-receptor imaging in the localization of endocrine tumors

1 reference

12 December 2020

Changing paradigms with molecular imaging of neuroendocrine tumors

1 reference

12 December 2020

QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies

1 reference

12 December 2020

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas

1 reference

12 December 2020

Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases.

1 reference

12 December 2020

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

1 reference

12 December 2020

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

12 December 2020

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated

1 reference

12 December 2020

The ACR Appropriateness Criteria: view from the committee chair

1 reference

12 December 2020

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

1 reference

12 December 2020

68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

1 reference

12 December 2020

Detection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion

1 reference

12 December 2020

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

1 reference

12 December 2020

Measured human dosimetry of 68Ga-DOTATATE.

1 reference

12 December 2020

Long-term survival after surgical management of neuroendocrine hepatic metastases

1 reference

12 December 2020

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

1 reference

12 December 2020

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide

1 reference

12 December 2020

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

12 December 2020

Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.

1 reference

12 December 2020

Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients

1 reference

12 December 2020

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.

1 reference

12 December 2020

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

1 reference

12 December 2020

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

1 reference

12 December 2020

Appropriate use of cardiovascular technology: 2013 ACCF appropriate use criteria methodology update: a report of the American College of Cardiology Foundation appropriate use criteria task force

1 reference

12 December 2020

Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography.

1 reference

12 December 2020

In support of the ACR Appropriateness Criteria

1 reference

12 December 2020

Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine

1 reference

12 December 2020

Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma

1 reference

12 December 2020

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

1 reference

12 December 2020

Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.

1 reference

12 December 2020

68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis.

1 reference

12 December 2020

Appropriateness and imaging utilization: "computerized provider order entry and decision support".

1 reference

12 December 2020

Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis

1 reference

12 December 2020

The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.

1 reference

12 December 2020

Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.

1 reference

12 December 2020

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

1 reference

12 December 2020

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

1 reference

12 December 2020

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

1 reference

12 December 2020

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

12 December 2020

Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor

1 reference

12 December 2020

Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes

1 reference

12 December 2020

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.

1 reference

12 December 2020

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance

1 reference

12 December 2020

[Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].

1 reference

12 December 2020

Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.

1 reference

12 December 2020

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

12 December 2020

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

1 reference

12 December 2020

External validation of a measurement tool to assess systematic reviews (AMSTAR).

1 reference

12 December 2020

Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?

1 reference

12 December 2020

Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.

1 reference

12 December 2020

10.2967/JNUMED.117.202275

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

PubMed publication ID

29025982

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29025982%20AND%20SRC:MED&resulttype=core&format=json